« Back to Medicines list

Pred Mild

  • Name:

    Pred Mild

  • Company:
    info
  • Active Ingredients:

    Prednisolone Acetate

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 31/03/21

files-icon(Click to Download)

XPIL

Summary of Product Characteristics last updated on medicines.ie: 31/3/2021

Click on this link to Download PDF directly

Allergan Ltd

Allergan Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Acular Active Ingredients Ketorolac Trometamol
Medicine Name Alphagan Active Ingredients brimonidine tartrate
Medicine Name Betagan Unit Dose Active Ingredients Levobunolol hydrochloride
Medicine Name BOTOX 100 Units Active Ingredients Botulinum Toxin Type A
Medicine Name BOTOX 200 Units Active Ingredients Botulinum Toxin Type A
Medicine Name BOTOX 50 Units Active Ingredients Botulinum Toxin Type A
Medicine Name Celluvisc 0.5% Active Ingredients Carmellose sodium
Medicine Name Celluvisc 1.0% w/v Eye drops, solution Active Ingredients Carmellose sodium
Medicine Name Combigan Active Ingredients brimonidine tartrate, Timolol Maleate
Medicine Name Exocin Active Ingredients Ofloxacin
Medicine Name FML Active Ingredients Fluorometholone
Medicine Name Ganfort Active Ingredients Bimatoprost, Timolol Maleate
Medicine Name Ganfort SD Active Ingredients Bimatoprost, Timolol Maleate
Medicine Name Lacri-Lube Active Ingredients No Active Ingredients
Medicine Name Liquifilm Tears Active Ingredients Polyvinyl Alcohol
Medicine Name Lumigan 0.1mg/ml Active Ingredients Bimatoprost
Medicine Name Ozurdex Active Ingredients Dexamethasone
Medicine Name Pred Forte Active Ingredients Prednisolone Acetate
Medicine Name Pred Mild Active Ingredients Prednisolone Acetate
Medicine Name Refresh Ophthalmic Active Ingredients Polyvinyl Alcohol, Povidone
Medicine Name Relestat 0.5 mg/ml, eye drops, solution Active Ingredients Epinastine Hydrochloride
Medicine Name Vistabel Active Ingredients Botulinum Toxin Type A
1 - 0 of 22 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 31 March 2021 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2 (qualitative and quantitative composition), boric acid 1% w/v was added as an excipient with known effect.

In section 4.4 (special warnings and precautions for use), information regarding excipient boron was added.  Pred Mild should not be used in children less than 12 years old because of safety concerns over impairment of fertility.

In section 4.8 (undesirable effects), HPRA contact details were updated.

In section 10 (date of revision of the text), the revision date was updated to February 2021.

Updated on 31 March 2021 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - use in children and adolescents
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 10 May 2018 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 5 February 2018 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 5 February 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 February 2018 SPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

  • In section 4.8 (undesirable effects), eye pain was added.
  • In section 10 (date of revision of text), the revised date was added.

Updated on 5 February 2018 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Change to section 2 - what you need to know - warnings and precautions

Updated on 5 December 2017 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.4 (special warnings and precautions for use), a visual disturbance warning was added.

In section 4.8 (undesirable effects), a note was added to see section 4.4 for further information on blurred vision.

In section 10 (date of the revision of the text), the date of revision was updated to September 2017.

Updated on 4 December 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 17 February 2017 SPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

-In section 4.5 (Interaction with other medicinal products and other forms of interaction) - update to indicate the increased risk of systemic side effects from co-treatment with CYP3A inhibitors, including cobicistat-containing products, following PRAC recommendation on signals adopted at the PRAC meeting in October 2016 and published by EMA in November 2016. The following wording, as requested by PRAC, has been added:

 Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.

 -In section 10 (Date of revision of the text) - the date of revision of the text is February 2017

Updated on 16 February 2017 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 23 October 2014 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

To update SPC in line with CCDS V3

Updated on 23 October 2014 PIL

Reasons for updating

  • Change of contraindications
  • Change to instructions about missed dose
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to further information section
  • Change to date of revision

Updated on 14 December 2009 SPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5 - Pharmacological properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company



Summary of Changes to Pred Mild® Irish Summary of Product Characteristics (SPC)

 

The current Pred Mild® SPC is dated November 2009

This supersedes SPC dated February 2008

 

 

Section Number

Subject

Change

4.2

Posology and method of administration

Text added

Shake well before use

Safety and effectiveness in paediatric patients have not been established. No posology can be recommended.

 

To reduce possible systemic absorption, it may be recommended that the lacrimal sac be compressed at the medial canthus (punctal occlusion) for 1 minute. This should be performed immediately following the instillation of each drop

4.4

Special warnings and precautions for use

Text added

Safety and effectiveness have not been demonstrated in children of the age group two years or below.

 

Systemic adverse events may occur with extensive use of topical steroids; punctal occlusion may be recommended (see Section 4.2).

 

Pred Mild contains benzalkonium chloride, which is irritant to the eye and could cause discoloration of soft (hydrophilic) contact lenses. The patient should avoid contact with contact lenses and therefore be instructed to remove them before Pred Mild is used and then wait for at least 15 minutes before reinsertion.

 

Pred Mild contains sodium metabisulphite, a sulphite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes. Sulphite sensitivity is seen more frequently in asthmatic patients.

 

 

4.6

Pregnancy and lactation

Text added

Administration of corticosteroids to pregnant animals has been associated with abnormalities of foetal development therefore this product should be used with caution during pregnancy only if the potential benefit outweighs the potential risk to the foetus.

4.7

Effects on ability to drive and use machines

Text added

Upon instillation, patients may experience transient blurred vision which may impair the ability to drive or use machinery. If affected, patients should not drive or use machinery until their vision has cleared.

 

Text deleted

Non known

4.8

Undesirable effects

Text added

Frequency categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from available data).

 

Immune system disorders

Not known:        Hypersensitivity,

                        Urticaria

 

Nervous system disorders

Not known:        Headache

 

Eye disorders   

Not known:       Intraocular pressure increased*

                        Cataract (including subcapsular)*           

Eye penetration (scleral or corneal perforation) *   

                        Eye infection fungal*

                        Eye infection viral*

                        Eye irritation

                        Vision blurred/Visual impairment            

Mydriasis

 

Gastrointestinal disorders

Not known:        Dysgeusia

Skin and subcutaneous tissue disorders

Not known:        Pruritus,

                        Rash

 

Systemic side effects may occur rarely with extensive use of topical steroids.*

 

* See Section 4.4 for further information.

 

Text deleted

The following events have been reported since the product was marketed:

Eye irritation.

Increased intraocular pressure which may be associated with optic nerve damage and defects in the visual fields.

Posterior subcapsular cataract formation.

Secondary ocular infections from fungi or viruses liberated from ocular tissues. Perforation of the globe when used in conditions where there is thinning of the cornea or sclera.

 

5.1

Pharmacodynamic properties

Text added

Pharmacotherapeutic group: corticosteroids,

ATC code: S01BA04

10

Date of revision of text

Text added

September 2009

Replaces

February 2008

 

 

Updated on 9 December 2009 PIL

Reasons for updating

  • Change due to harmonisation of patient information leaflet

Updated on 24 June 2008 SPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8 Added:
The following events have been reported since the product was marketed: Eye irritation.
Section 10 Changed to: 27th February 2008

Updated on 12 June 2008 PIL

Reasons for updating

  • Change to date of revision

Updated on 30 August 2007 SPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 7 - Marketing authorisation holder
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Due to the extent of changes please follow the link below:
 

Updated on 28 August 2007 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 16 August 2005 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 9 August 2004 PIL

Reasons for updating

  • New PIL for new product

Updated on 27 August 2003 SPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 27 June 2003 SPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)